Gujarat Themis Biosyn Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rz5ulhdmf23my4r53pindct3.pdf

Key Takeaways


Rifapentine: The Volume & Value Thesis

Dr. Sachin Patel: "It's a new kid on the block, the upside is massive, the pricing is extremely interesting right now. So, the numbers could be significantly different from what we are seeing right now, but it all depends upon how Rifapentine as a product picks up."

Capacity Build-Out & CAPEX


Margins: The R&D Investment Overhang

Dr. Sachin Patel: "So, for a long time, we were waiting for our R&D block to come up and now that it is almost there, influx of people, at the same time things happening, materials coming in. So, it's a bit of an action-packed high if I may say so."

Customer Concentration & Competitive Dynamics

Dr. Sachin Patel: "I think everyone has prepared themselves for whatever has to be done in the future to make sure that they have their business secured, it's not just us or our partners or someone else who's in the market, everyone would take care because the investments that are required in this kind of a project are quite significant."

Operations & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Phase-I API block commissioningTrials and commercialization to followDecember 2023
Quarterly revenue run-rateBroadly around ₹40 croresUntil new API block revenue starts (mid next financial year)
Phase-III CAPEX finalizationAt least double the initial ~₹200 crores planTo be reported once finalized
Phase-III CAPEX funding decisionDebt vs. equity vs. mixNext six to nine months
New fermentation capacityConstruction underwayReady by 2025
Rifapentine global tendersExpected to materializeDuring the course of a year or two years

Key Metrics

MetricQ2 FY24
Revenue₹39.65 cr, vs ₹47.69 cr in Q2 FY23
EBITDA₹16.82 cr, down 31% YoY
EBITDA margin42.42%, down 875 bps YoY; impacted by R&D costs, skilled workforce investments, and one-time expenses
PAT₹12.54 cr, vs ₹18.7 cr in Q2 FY23
PAT margin31.63%
EPS₹8.63 per share
H1 FY24 Revenue₹89.24 cr, down 3.66% YoY
H1 FY24 EBITDA margin45.19%
H1 FY24 PAT₹30.27 cr, vs ₹36 cr in H1 FY23
H1 FY24 EPS₹20.83 per share
CAPEX under work-in-progress₹60 cr
Capacity utilizationMore than 100%, selling as producing with no carry-forward inventory; last FY was 75–80%
Rifapentine API capacity built7 to 8 MT per month, multi-purpose facility
Phase-I CAPEX spent in last 2.5 years~₹78 cr (₹14 cr in FY22, ₹24 cr in FY23, ₹41 cr in H1 FY24)
New CAPEX plan indicationAt least double the initial ~₹200 cr plan, not yet finalized